Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AN2 Therapeutics, Inc. - Common Stock (NQ: ANTX )

1.070 +0.010 (+0.94%)
Streaming Delayed Price Updated: 10:00 AM EDT, Sep 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 17,286
Open 1.070
Bid (Size) 1.070 (30)
Ask (Size) 1.080 (5)
Prev. Close 1.060
Today's Range 1.060 - 1.080
52wk Range 0.8700 - 22.22
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From AN2 Therapeutics, Inc.
Via Business Wire
AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan
From AN2 Therapeutics, Inc.
Via Business Wire

Performance

YTD
-94.61%
-94.61%
1 Month
+1.90%
+1.90%
3 Month
-48.31%
-48.31%
6 Month
-66.67%
-66.67%
1 Year
-92.12%
-92.12%

More News

Read More
Citizens And 2 Other Penny Stocks Insiders Are Buying
Via Benzinga
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
Why Is AN2 Therapeutics (ANTX) Stock Down 35% Today?
Via InvestorPlace
Crude Oil Rises; Blend Labs Shares Jump Following Q2 Results
Via Benzinga
Exposures Fossil Fuels
US Stocks Edge Lower; EchoStar Shares Tumble After Q2 Results
Via Benzinga
Lung Disease Focused AN2 Therapeutics' Lackluster Data Prompts To Stop Phase 3 Study Of Lung Infection Candidate, Halves Workforce
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease
From AN2 Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q1 2024
Via InvestorPlace
AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q4 2023
Via InvestorPlace
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
From AN2 Therapeutics, Inc.
Via Business Wire
ZoomInfo Technologies To Rally Around 50%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Nasdaq Edges Lower; ContextLogic Shares Surge
Via Benzinga
Topics Stocks
Exposures US Equities
Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B
Via Benzinga
Topics Stocks
Exposures US Equities
US Stocks Mixed; Trimble Issues Weak Outlook
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Infectious Disease-Focused AN2 Therapeutics Stock Sinking Today?
Via Benzinga
Monday.com Reports Q4 Results, Joins AN2 TherapeuticsAnd Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.